In an investigation of alternative therapeutic approaches for the treatment of influenza virus infections, the antiviral activities of rimantadine hydrochloride, amantadine hydrochloride, ribavirin, and combinations of these drugs were assessed in vitro. Madin-Darby canine kidney cell monolayers were inoculated with recent isolates of influenza viruses at low multiplicities of infection, and virus titers were determined after 24 h. The combination of rimantadine and ribavirin resulted in an enhanced antiviral effect (a decrease in virus titer of >1.0 logio plaque-forming unit per ml at 24 h relative to the maximal effect of a single drug) against A/USSR/90/77/H1N1, A/Texas/1/77/H3N2, A/New Jersey/76/ HSWlN1, and A/PR/834/HON1 viruses. The degree of inhibition depended on the virus strain used, the drug concentrations, and the virus inoculum. Amantadine and ribavirin showed enhanced activity. Ribavirin in combination with high (50 ,ug/ml), but not low (1.56 to 25 ,ug/ml), concentrations of rimantadine showed an enhanced antiviral effect against B/Hong Kong/72 virus. An assay of MadinDarby canine kidney cell proliferation in the presence of drugs showed that the enhanced inhibitory effect of drug combinations was not due to increased cytotoxicity.
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The adamantane compounds amantadine hydrochloride (Symmetrel) and rimantadine hydrochloride have well documented prophylactic and therapeutic activities against uncomplicated human influenza A virus infections (6, 17, 27 ; L. P. VanVoris, R. B. Betts, F. G. Hayden, W. A. Christman, and R. G. Douglas, Jr., Program Abstr. Intersci. Conf. Antimicrob. Agents, Chemother. 18th, Atlanta, Ga., abstr. no. 483). Anecdotal evidence suggests that high doses of amantadine may have a beneficial effect against influenza viral pneumonia (5) . However, no specific therapy of proven value presently exists for treatment of serious influenza virus infections, including primary viral and mixed viral-bacterial pneumonias. Ribavirin (Virazole) has antiviral activity against influenza A and influenza B viruses in vitro (11, 19) and in animal models of influenza, but clinical trials have found little evidence of therapeutic effectiveness (4, 16, 23, 26) . In an effort to develop alternative therapeutic approaches to single-drug therapy, the present study was undertaken to determine the antiviral activities of combinations of these drugs in vitro. The results indicated that the combination of rimantadine hydrochloride and ribavirin exerted an enhanced antiviral effect against influenza viruses compared with the effects of single drugs. Drug studies. The in vitro inhibitory activities of drugs alone and in combinations were determined as follows. Confluent monolayers of MDCK cells grown in 24-well plates as described above were inoculated in quadruplicate with 0.2-ml volumes of virus suspension. Except for experiments to determine the effects of virus inocula the multiplicities of infection ranged from 10-3 to 10-4 PFU/monolayer cell. After a 60-min adsorption period at 36°C, Eagle minimal essential media containing trypsin (final concentration, 2 jug/ ml) and the appropriate drug dilutions were added to the wells. The drug dilutions were selected to include concentrations that have been found to inhibit influenza virus plaque production in MDCK cell monolayers (10) . After incubation at 36°C for 24 h, the supernatants from quadruplicate wells were harvested and pooled. Portions were frozen at -70°C for later titration. In certain experiments the monolayers were refed with freshly prepared, drug-containing medium, and repeat harvests were made at 48 and 72 h after the initial virus inoculation.
The parameters of virus replication tested were estimation of cytopathic effects and titration of infectivity by the plaque assay described above. Enhancement of antiviral activity was considered to be present if a combination of drugs resulted in a more than 90% decrease (>1.0 log10 PFU/ml) in virus yield at 24 h compared with the effect of either drug alone. A synergistic interaction of a combination was defined as a decrease in virus yield at 24 h that was greater than the algebraic sum of the decreases observed with single drugs (13) .
Drug cytotoxicity. Rimantadine alone at 0.1 ,ug/ml resulted in a decrease in virus yield of 2.5 logio PFU/ml, but increasing concentrations of rimantadine over a 15-fold range did not increase this degree of inhibition. The additional decrease in virus yield observed with the addition of ribavirin at a fixed dose was less than 0.6 logio PFU/ml at the lower rimantadine concentrations, but increased to over 1. 8 logs at the highest concentration tested. Table 3 shows the effect of varying ribavirin concentrations from 0 to 6.25 ,ug/ml while holding the rimantadine concentration at 1.56 ,g/ml for A/Texas/1/77/H3N2. The values listed are the means of three experiments. In contrast to rimantadine, ribavirin alone demonstrated a dose-response inhibition of virus yield at 24 h that ranged from a reduction of 0.9 logio PFU/ ml at 1.56 Ag/ml to a reduction of 3.5 logio PFU/ ml at 6.25 ug/ml. The additional decrease in virus yield observed with the addition of rimantadine at 1.56 ,g/ml was 0.4 logio PFU/ml or b Additional decrement in virus yield with drug combination beyond the algebraic sum of the decreases observed with either single drug.
that used in the experiments described above, and the combination of 1.56 pg of rimantadine per ml and 3.12 ,ug of ribavirin per ml resulted in an additional reduction in virus yield at 24 h of 1.3 logio PFU/ml compared with the sum of the effects observed with each drug alone. With 100-fold-greater virus inoculum, the inhibitory effects of single drugs, particularly rimantadine, and of the combination decreased sharply but were still present. At a virus input equivalent to 1 PFU/cell, antiviral activity, as defined by an inhibition of virus yield of at least 1 logio, was not apparent. Whether increasing drug concentrations could overcome this inoculum effect was not studied.
Drug cytotoxicity. High rimantadine concentrations (50 ,ug/ml), alone and in combination with ribavirin, resulted in slight visible cytopathic effects. No obvious cytopathic effects were apparent at the highest ribavirin concentration (12.5 ,ug/ml) studied. As Table 5 shows, MDCK cell proliferation at 48 and 72 h decreased in the presence of ribavirin in a dose- 3 .12 ,ug of ribavirin per ml and did not increase in those exposed to 6.25 ,ug of ribavirin per ml. The addition of 1.56 ,ug of rimantadine per ml did not further depress MDCK cell proliferation.
DISCUSSION
We found that the combination of rimantadine hydrochloride and ribavirin had greater antiviral activity against influenza A viruses in vitro than either drug alone. Previously, Galegov et al. reported an increased antiviral effect with rimantadine hydrochloride and ribavirin in in vitro experiments with an avian influenza A virus and in mouse protection experiments with influenza A2/Frunze virus (7) . The present study extended this observation to include contemporary human strains and multiple serotypes of influenza A viruses. In addition, an enhanced antiviral effect was demonstrated against the relatively rimantadine-resistant A/PR/8/HON1 virus and, with high rimantadine concentrations, against an influenza B virus. The present study also showed that combinations of a related drug, amantadine hydrochloride, and ribavirin had enhanced antiviral effects against influenza A viruses.
The degree of inhibition from the drug combinations depended not only on the virus strain, but also on the virus inoculum. The inhibitory effects of single drugs or combinations were overcome at higher multiplicities of infection. An inoculum effect has been recognized previously in drug susceptibility tests with amantadine and rimantadine (7, 9) . Galegov et al. found that the combination of rimantadine hydrochloride and ribavirin continued to demonstrate an enhanced antiviral effect despite progressively higher multiplicities of infection, although eightfold-higher ribavirin concentrations were used in their study than in the present one.
The antiviral effects of ribavirin and rimantadine combinations were also dose dependent. In contrast to the findings of Galegov et al., ribavirin alone at concentrations of 12. 5 and 6.25 ,pg/ml resulted in marked inhibition of influenza A virus multiplication. This single drug activity masked any potential augmentation of antiviral effects with the addition of rimantadine. In contrast, rimantadine alone showed a relatively constant inhibitory effect over a broad concentration range. The addition of ribavirin at a fixed concentration resulted in substantially greater antiviral activity in combination with high ri-ANTIMICROB. AGENTS CHEMOTHER.
mantadine concentrations compared with low ones.
The mechanism of enhancement of antiviral activity due to drug combinations was not determined in the present study. For certain drug combinations the extent of inhibition of virus multiplication was greater than the additive effects of the single drugs, and this finding suggested a synergistic interaction (13) . Although rimantadine and ribavirin appear to affect different stages of influenza virus replication, the antiviral mechanisms of these drugs alone have not been fully elucidated (18, 19, 21, 22) . Another possible Inechanism of enhanced antiviral activity with combinations of drugs may be inhibition of the selection and multiplication of drug-resistant viruses. Exposure of influenza A viruses in vitro has been shown to select drug-resistant viruses (3, 20) . However, preliminary studies with the present assay methods have not detected a substantial shift toward drug resistance after exposure to single drugs.
The enhanced antiviral effects of the combinations were probably not secondary to increased cytotoxicity. The ribavirin concentrations used in this study inhibit ribonucleic acid synthesis in uninfected MDCK cells (2) . Previous studies have shown an inhibitory effect on manmalian cell proliferation at higher concentrations (11, 14; J. F. Hruska, personal communication), but we observed inhibition of MDCK cell proliferation at concentrations of from 3.12 to 12.5 ,ug/ml. However, the combination of ribavirin and rimantadine did not result in an additional anti-proliferative effect.
The clinical significance of these observations remains to be determined. Enhanced antiviral effects against influenza A viruses were demonstrated with rimantadine concentrations of 0.1 to 0.4 Ag/ml, which are well within the range of achievable blood levels after oral administration (1, 8) . In contrast, the ribavirin concentrations used in the present study are approximately 5-to 10-fold higher than those reported after oral administration in human subjects (12) . However, these results do provide impetus for further investigations of drug combinations for antiviral therapy in other models of influenza infection.
